An international team applied a type 1 diabetes genetic risk score in a large adult cohort, showing that individuals in the top decile had roughly eight‑times higher odds of being in presymptomatic, autoantibody‑positive stages of disease compared with the rest of the population. Combining the score with targeted islet‑autoantibody testing offers an efficient pathway to identify adults who could benefit from therapies that delay clinical onset. This approach supports integrating polygenic risk into population‑level screening as disease‑modifying agents become more widely available. To read more Click Here ##Reference## Thomas, N J et al.
Genetic risk-targeted islet autoantibody screening for presymptomatic type 1 diabetes in adults. The Lancet Diabetes & Endocrinology, Volume 14, Issue 1, 11 - 13## In your experience, what would be the most acceptable first step to bring presymptomatic…
